PARP inhibitors in ovarian cancer: Overcoming resistance with combination strategies

31Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with an increasing population of patients who develop acquired PARPi resistance. Coupled with those patients with primary PARPi resistance, there is an urgent need to better understand mechanisms of resistance and identify means to overcome this resistance. Combination therapy offers the potential to overcome innate and acquired resistance, by either working synergistically with PARPi or by restoring homologous recombination deficiency, targeting the homologous recombination repair pathway through an alternate strategy. We discuss mechanisms of PARPi resistance and data on novel combinations which may restore PARPi sensitivity.

Cite

CITATION STYLE

APA

Miller, R. E., El-Shakankery, K. H., & Lee, J. Y. (2022, May 1). PARP inhibitors in ovarian cancer: Overcoming resistance with combination strategies. Journal of Gynecologic Oncology. Korean Society of Gynecologic Oncology and Colposcopy. https://doi.org/10.3802/jgo.2022.33.e44

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free